Zydus Lifesciences Buyback Guidance & Details

About Zydus Lifesciences :
Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide. Zydus’ Innovation programme is spearheaded by 1400 researchers across 19 sites, working on differentiated medicines for the future.
From NCEs to vaccines, biosimilars and niche technologies, the group is exploring different ideas and concepts, innovating constantly. As one of the key players amongst the pharmaceutical manufacturing companies, the group has manufacturing capabilities across the entire pharmaceutical value chain: including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products and wellness products. It has more than 30 manufacturing plants worldwide including India, Brazil and USA.
The India Business comprises the India formulations business spearheaded by Zydus Healthcare Ltd., based in Mumbai and the Biologics business which drives the sales and marketing of biosimilars and novel biologics. Zydus is one of the oldest players in the Indian formulations market and has gone onto become a prominent pharmaceutical manufacturer in India. Besides continuously improving its market presence and market share, the group has also expanded its portfolio by entering newer therapeutic areas.The group has been launching new products with the first mover advantage and has a strong presence in both acute and chronic therapies.
For more information, visit company website : https://www.zyduslife.com/index

Necessity of the Zydus Lifesciences Buyback
The buyback is a capital allocation decision taken by the company.
1. The Buyback will help the company to distribute a part of surplus cash to its shareholders holding Equity shares thereby optimising returns to the shareholders and enhancing the overall shareholders’ value in longer term and improving the return on Equity.

Zydus Lifesciences Buyback Detail
Issue Period
Security Name Zydus Lifesciences Limited
Issue Type Tender Offer
Issue Size (Shares) 115,38,461 Shares
Issue Size (Amount) Rs 750.00 Crores
Buyback Price Rs 650 per share
Face Value Re 1 per share
Listing At BSE, NSE

Zydus Lifesciences Buyback Ratio
15% of the Equity shares which the company proposes to buyback are entitled as per the shareholding of Small investors.
Category & Entitlement Ratio of Buyback
Reserved Category for Small Shareholders (?)
General Category for all other Eligible Shareholders (?)

Zydus Lifesciences Buyback Issue Timetable
Offer Opens On (?)
Offer Closes On (?)
Record Date Jun 2, 2022
Last Date for receipt of Tender Forms : (?)
Finalisation of Buyback Acceptance : (?)
Last Date for settlment of bids : (?)
Last Date for Extinguishment of Shares
Last Date for settlment of bids Jun 1, 2022
Last Date for Extinguishment of Shares Jun 8, 2022

Registered Office of Zydus Lifesciences Limited
Zydus Lifesciences Limited
Zydus Corporate Park, Scheme No. 63,
Khoraj (Gandhinagar), 536, Sarkhej-Gandhinagar Hwy
Near Vaishnodevi Circle, Ahmedabad, 382481

Manager to the Zydus Lifesciences Buyback
ICICI Securities ltd
Zydus Lifesciences Buyback Registrar
Link Intime India Pvt Limited
Company Secretary & Compliance Officer : Dhaval Soni

Buyback Guidance by Paresh Gordhandas , Research Analyst

Click